FibroGen, Inc. (KYNB)
NASDAQ · Healthcare
FibroGen, Inc. EBITDA 2020–2025
FibroGen, Inc. annual/quarterly ebitda history and growth rate from 2020 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- FibroGen, Inc. ebitda for the quarter ending March 31, 2026 was -12.7 M, a 9.81% decrease year-over-year.
- FibroGen, Inc. ebitda for the twelve months ending March 31, 2026 was -40.3 M.
- FibroGen, Inc. annual ebitda for 2025 was -41.7 M, a 66.13% decrease from 2024.
- FibroGen, Inc. annual ebitda for 2024 was -123.0 M, a 50.57% decrease from 2023.
- FibroGen, Inc. annual ebitda for 2023 was -248.8 M, a 12.03% decrease from 2022.
- FibroGen, Inc. annual ebitda for 2022 was -282.8 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
FibroGen, Inc. EBITDA — FAQ
FibroGen, Inc. (KYNB) ebitda over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see KYNB's ebitda history?
The chart and table above show FibroGen, Inc.'s ebitda by year and by quarter, including the growth rate.